CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 3, Randomized, Observer-blinded, Active-controlled Trial to Evaluate Immunogenicity & Safety of a Recombinant Quadrivalent Nanoparticle Influenza Vaccine (Quad-NIV) With Matrix-M1™ Adjuvant Against Fluzone® Quadrivalent in Clinically Stable Adults ≥ 65 Years of Age

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT04120194
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:39:11.511428+00:00
Published At: 2023-05-06T00:00:00+00:00
Record Updated At: 2023-05-06
Results Posted At: 2023-05-06
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Influenza, Human"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2023-05-06"
protocolSection.identificationModule.nctId: "NCT04120194"
protocolSection.identificationModule.officialTitle: "A Phase 3, Randomized, Observer-blinded, Active-controlled Trial to Evaluate Immunogenicity \u0026 Safety of a Recombinant Quadrivalent Nanoparticle Influenza Vaccine (Quad-NIV) With Matrix-M1\u2122 Adjuvant Against Fluzone\u00ae Quadrivalent in Clinically Stable Adults \u2265 65 Years of Age"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE3"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2023-05-06"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.